OKYO Pharma Announces Successful Type C Meeting with the FDA

Summary by AI BETAClose X

OKYO Pharma has announced a successful Type C meeting with the FDA regarding the Phase 2b/3 clinical trial of urcosimod for neuropathic corneal pain (NCP), confirming the primary endpoint of Visual Analogue Scale (VAS) pain reduction at Week 12 with a ≥2-point improvement considered meaningful. The FDA endorsed the study design, sample size, and powering assumptions, deeming the Ocular Pain Assessment Survey (OPAS) appropriate for quality-of-life data, and raised no material issues with the CMC strategy, de-risking the path to a pivotal trial. The company plans to initiate a 120-patient Phase 2b/3 study in the first half of the year, building on prior positive data and Fast Track designation.

Disclaimer*

UK 100

Latest directors dealings